Lanying Du

TL;DR: Recent advances in the development of vaccines and therapeutics based on the S protein are highlighted, which plays key parts in the induction of neutralizing-antibody and T-cell responses, as well as protective immunity, during infection with SARS-CoV.

TL;DR: The receptor-binding domain (RBD) in SARS-CoV-2 S protein was identified and it was found that the RBD protein bound strongly to human and bat angiotensin-converting enzyme 2 (ACE2) receptors and could block the binding and, hence, attachment of SARs-Cov-2 RBD and SARS -CoV RBD to ACE2-expressing cells, thus inhibiting their infection to host cells.

TL;DR: EK1C4 was the most potent fusion inhibitor against SARS-CoV-2 S protein-mediated membrane fusion and pseudovirus infection with IC50s of 1.3 and 15.8 nM, about 241- and 149-fold more potent than the original EK1 peptide, respectively.

TL;DR: Advances in the research and development of neutralizing antibodies (nAbs) for the prevention and treatment of infection by SARS-CoV-2 and other human CoVs are discussed.

TL;DR: A neutralizing monoclonal antibody, which targets the receptor-binding domain of Middle East respiratory syndrome (MERS) coronavirus spike, mediates viral entry using pseudovirus entry and biochemical assays, and results showed that MAb binds to the virus surface spike, allowing it to undergo conformational changes and become prone to proteolytic activation.